- Home
- GYRE vs BFST Comparison
GYRE vs BFST Comparison
Compare GYRE & BFST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRE
- BFST
- Stock Information
- Founded
- GYRE 2002
- BFST 2006
- Country
- GYRE United States
- BFST United States
- Employees
- GYRE N/A
- BFST N/A
- Industry
- GYRE Biotechnology: Pharmaceutical Preparations
- BFST Major Banks
- Sector
- GYRE Health Care
- BFST Finance
- Exchange
- GYRE Nasdaq
- BFST Nasdaq
- Market Cap
- GYRE 897.1M
- BFST 724.9M
- IPO Year
- GYRE N/A
- BFST 2018
- Fundamental
- Price
- GYRE $9.07
- BFST $23.79
- Analyst Decision
- GYRE
- BFST Buy
- Analyst Count
- GYRE 0
- BFST 2
- Target Price
- GYRE N/A
- BFST $30.00
- AVG Volume (30 Days)
- GYRE 332.9K
- BFST 78.3K
- Earning Date
- GYRE 05-09-2025
- BFST 04-24-2025
- Dividend Yield
- GYRE N/A
- BFST 2.34%
- EPS Growth
- GYRE N/A
- BFST N/A
- EPS
- GYRE 0.02
- BFST 2.43
- Revenue
- GYRE $100,643,000.00
- BFST $276,739,000.00
- Revenue This Year
- GYRE $22.01
- BFST $25.40
- Revenue Next Year
- GYRE $88.14
- BFST $5.33
- P/E Ratio
- GYRE $120.95
- BFST $9.84
- Revenue Growth
- GYRE N/A
- BFST 11.75
- 52 Week Low
- GYRE $6.11
- BFST $18.97
- 52 Week High
- GYRE $19.00
- BFST $30.30
- Technical
- Relative Strength Index (RSI)
- GYRE 45.78
- BFST 48.39
- Support Level
- GYRE $9.26
- BFST $23.25
- Resistance Level
- GYRE $11.61
- BFST $24.33
- Average True Range (ATR)
- GYRE 1.09
- BFST 0.54
- MACD
- GYRE -0.21
- BFST -0.06
- Stochastic Oscillator
- GYRE 28.12
- BFST 29.11
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
About BFST Business First Bancshares Inc.
Business First Bancshares Inc is a bank holding company. The company's services include personal and commercial banking, treasury management, and wealth solutions. It provides a range of financial services to small-to-midsized businesses and professionals. The company generates majority of its revenues from interest income on loans, customer service and loan fees, and interest income from securities.